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Abstract
Background: A woman of reproductive age often harbors a small number of foreign cells, referred to as microchimerism: a
preexisting population of cells acquired during fetal life from her own mother, and newly acquired populations from her
pregnancies. An intriguing question is whether the population of cells from her own mother can influence either maternal
health during pregnancy and/or the next generation (grandchildren).
Methodology/Principal Findings: Microchimerism from a woman’s (i.e. proband’s) own mother (mother-of-the-proband,
MP) was studied in peripheral blood samples from women followed longitudinally during pregnancy who were confirmed
to have uncomplicated obstetric outcomes. Women with preeclampsia were studied at the time of diagnosis and
comparison made to women with healthy pregnancies matched for parity and gestational age. Participants and family
members were HLA-genotyped for DRB1, DQA1, and DQB1 loci. An HLA polymorphism unique to the woman’s mother was
identified, and a panel of HLA-specific quantitative PCR assays was employed to identify and quantify microchimerism.
Microchimerism from the MP was identified during normal, uncomplicated pregnancy, with a peak concentration in the
third trimester. The likelihood of detection increased with advancing gestational age. For each advancing trimester, there
was a 12.7-fold increase in the probability of detecting microchimerism relative to the prior trimester, 95% confidence
intervals 3.2, 50.3, p,0.001. None of the women with preeclampsia, compared with 30% of matched healthy women, had
microchimerism (p=0.03).
Conclusions/Significance: These results show that microchimerism from a woman’s own mother is detectable in normal
pregnancy and diminished in preeclampsia, supporting the previously unexplored hypothesis that MP microchimerism may
be a marker reflecting healthy maternal adaptation to pregnancy.
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Introduction
Small numbers of maternal cells, acquired during fetal life,
persist into adult life in healthy individuals as microchimerism
[1,2]. This microchimeric population of cells is partially genetically
foreign to the person who harbors them, as the cells also express
non-inherited maternal antigens (NIMA). Durable effects of
NIMA have been described in later life tolerance to organ grafts
as well as in susceptibility to some diseases [3,4]. These
observations raise the interesting question whether the micro-
chimerism a woman harbors from her mother can impact either
the course or outcome of her own pregnancies.
To our knowledge, microchimerism from a woman’s own
mother has not been studied during the course of pregnancy. We
therefore conducted longitudinal studies of microchimerism from a
woman’s mother across gestational age in healthy pregnancies. To
further explore a possible role for microchimerism from a woman’s
mother in maternal adaptation to pregnancy, we also sought to
determine whether detection of microchimerism differed in the
pregnancy complication preeclampsia, which is characterized by
maternal immune dysfunction [5,6].
Because a pregnant woman acquires another population of cells
from the fetus during pregnancy [7], the current studies
encompass three generations with more than one mother-child
relationship. For clarity in discussion we will refer to the pregnant
woman as the proband (P), to the mother of the pregnant woman
as the mother of the proband (MP), and the child as the child of
the proband, or fetus. Microchimerism from a woman’s own
mother will be referred to as MP microchimerism.
Materials and Methods
Ethics Statement
We obtained ethics approval for this study from the ethics
committee at all institutions/hospitals where the participants were
recruited and human experimentation was conducted, specifically
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Research Center and the University of Washington. All individual
participants gave written informed consent prior to participation
in the study. For all children involved in the study, written
informed parental consent was obtained. The form of assent/
consent from the children depended on their age; for children
aged 14 and years and older, written informed consent was
obtained, for children aged 7–13 years, written assent was
obtained, and for children less than 7 years old, verbal assent
was obtained. This process was approved by the Institutional
Review Board of the Fred Hutchinson Cancer Research Center,
which was the only institution where children were recruited.
Participants
We prospectively recruited healthy women with a singleton
pregnancy seeking obstetric care in Seattle, Washington, USA
between November 1995 and December 2008. Blood draws were
requested from subjects during each trimester, and when available,
preconception and postpartum.
After delivery, medical records and a self-reported questionnaire
were collected and reviewed for clinical and demographic
information. Information obtained included age, ethnicity,
medical history, reproductive history, dating of the pregnancy,
pregnancy complications, and maternal and fetal outcomes.
History of transfusion was also queried. To fulfill our first
objective, to describe the natural history of MP microchimerism
over normal gestation, previously established exclusionary criteria
were applied after delivery to restrict studies to women with a
normal outcome. For the normal pregnancy group, we excluded
subjects with the following obstetric complications: preterm birth
(spontaneous or indicated), gestational hypertension, preeclampsia,
diabetes, placenta previa, or placental abruption.
For the preeclampsia population, women were recruited at the
time of clinical diagnosis at the University of Washington Medical
Center. Preeclampsia was defined as hypertension (systolic blood
pressure .140 or diastolic blood pressure .90) persistent for at
least six hours with proteinuria (defined as a timed urine collection
with $300 mg of protein in 24 hours, a random urine sample with
a protein to creatinine ratio of $0?5, or a urine dipstick assessment
of $3+). Severe preeclampsia was defined by the presence of any
of the following: severe hypertension (systolic blood pressure .160
or diastolic blood pressure .110) persistent for at least six hours,
seizures (eclampsia), hemolysis, elevated liver enzymes, thrombo-
cytopenia, pulmonary edema, renal dysfunction, or fetal growth
restriction [8,9]. Subjects with chronic hypertension were included
if a timed urine collection from early in pregnancy was available,
and a twofold elevation in proteinuria was demonstrated in
conjunction with worsening hypertension. All samples were drawn
before the onset of labor. For the comparative analysis,
participants with preeclampsia were matched one to one with
healthy participants by gestational age and parity.
For all study probands, participation of the proband’s mother
was required for inclusion in the study, so that HLA-genotyping
could be conducted to identify a polymorphism unique to the MP
to target by HLA-specific quantitative PCR. Buccal swab
sampling, mouthwash collection, or a blood draw was requested
for this purpose. Fetal cord blood for genotyping was obtained
immediately after delivery. Other family members were also
invited to participate, including spouses/partners and any
previously born children.
Procedures
Isolation of Peripheral Blood Mononuclear Cells (PBMC)
and DNA Extraction. Peripheral venous blood samples were
drawn into acid citrate dextrose solution A-vacutainer tubes.
PBMC were isolated from whole blood by Ficoll Histopaque
(Pharmacia Biotech, Uppsala, Sweden) gradient centrifugation at a
density of 1.077 g/ml. Genomic DNA was extracted from PBMC
using Wizard Genomic DNA Purification Kits (Promega,
Madison, WI) according to manufacturer’s instructions. DNA
was extracted from mouthwash specimens using the High Pure
PCR Template Preparation Kit (Roche Diagnostics, Indianapolis,
IN) or from buccal swabs using the BuccalAmp DNA Extraction
Kit (Epicentre Biotechnologies, Wisconsin, USA).
Quantification of microchimerism by quantitative
PCR. Because of the extensive polymorphism in HLA genes,
HLA genotyping of probands and their mothers usually results in
identification of a polymorphism that is unique to the MP that can
then be targeted to identify and quantify MP microchimerism.
HLA genotyping was conducted using Dynal linestrips (prior to
January 2008) or Luminex-based (One Lambda, Canoga Park,
California, USA, beginning January 2008) PCR-sequence specific
oligonucleotide probe techniques. All probands and family
members were HLA-genotyped for the class II loci DRB1,
DQA1, and DQB1. Familial HLA relationships were examined to
identify non-shared HLA polymorphisms that could be used to
uniquely identify MP microchimerism (for example, see Figure 1).
In cases in which family HLA class II genotyping did not yield a
testable polymorphism unique to the MP, other polymorphisms
were typed including HLA-B and thyroglobulin deletion (Tg-
deletion).
After identifying a polymorphism that was unique to the MP for
each family, we employed the appropriate assay from a panel of
HLA- and other polymorphism-specific qPCR assays that we
developed for this purpose [10] to test DNA extracted from the
proband’s PBMC for MP microchimerism. Six to twelve aliquots
of DNA from PBMC were tested from each blood draw, with total
reaction volumes of 50 uL. The maximum amount of DNA tested
per aliquot was 25,000 genome equivalents (gEq), as higher
concentrations of DNA can inhibit the PCR reaction. A
calibration curve for the polymorphism-specific assay was included
to quantify the amount of MP microchimerism and validate the
assay for each experiment. Every sample was also tested for a non-
polymorphic gene, betaglobin (BGLOB). A BGLOB calibration
curve (obtained from commercially prepared human genomic
DNA [Promega]) was concurrently evaluated on each plate to
Figure 1. Schematic representation of strategy used to identify
microchimerism. In this example, HLA genotyping for DRB1 is shown
for a proband, her mother (MP), and her fetus. Once a polymorphism
unique to the MP is identified (DRB1*01 in this example), polymor-
phism-specific quantitative PCR can then be used to quantify MP
microchimerism in DNA extracted from proband PBMC.
doi:10.1371/journal.pone.0024101.g001
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tested in each reaction. DNA quantities were reported as the DNA
gEq number of MP cells per 100,000 proband cell equivalents by
using a conversion factor of 6.6 pg DNA per cell [11]. Total DNA
tested per sample was considered acceptable if greater than 30,000
gEq.
Multiple safeguards were taken to avoid the risk of contamina-
tion. The optical detection system of the 7000 Sequence Detector
obviates the need to reopen reaction tubes after amplification.
DNA extractions and qPCR preparations were performed under
an ultraviolet (UV) light equipped safety hood, with UV run for 30
minutes between experiments. Filtered tips were used during
pipetting. Each experiment included control wells to ensure the
absence of contamination.
Statistical methods
Each sample obtained during and prior to pregnancy was
described according to gestational age and trimester in pregnancy
(pre-pregnancy, first trimester: ,14 weeks, second trimester: 14–
28 weeks, third trimester: .28 weeks) using the expected delivery
date from the obstetrical provider’s best clinical estimate. All
subjects had sonographic confirmation of their dating during the
first or second trimester.
Testing for microchimerism relies on stochastic sampling of an
aliquot of proband cells (approximately 100,000 from each
peripheral blood draw). The distribution of this type of data most
closely approximates a Poisson process due to the rarity of
microchimerism by definition. Therefore, to examine the impact
of gestational age on changes in MP microchimerism levels in
PBMC during normal pregnancy, we fit models utilizing a Poisson
process for the rate of detection of MP microchimerism. This
method models the probability of observing one positive cell (1
gEq) out of the total number of cells examined (therefore also
accounting for any variations in total cell number tested). Due to
the high degree of over-dispersion in the data, we utilized a
negative-binomial model to obtain model estimates, with inter-
pretation of results identical to that of a Poisson regression model.
In the regression models, we analyzed increasing trends over the
course of pregnancy, reporting an average incidence rate ratio
(IRR) for change from one interval to the next (starting from
prepregnancy and across subsequent trimesters or weeks). For the
purposes of graphical presentation, a cubic spline function with 3
knots was fit as a function of weeks of pregnancy within the
negative binomial model, and predicted rates calculated to
illustrate the shape of the predicted rate of MP microchimerism
over time.
For the analysis comparing MP microchimerism to subjects with
preeclampsia, one control subject was identified for each
preeclampsia case, matching on parity and gestational age.
Overall detection of any MP microchimerism was compared
using McNemar’s test for matched pairs. Concentrations of MP
microchimerism were compared using the Wilcoxon matched
pairs signed rank test. All statistical analyses were conducted using
Intercooled STATA 11?0 for Windows 2000 (StataCorp, College
Station, Texas). All p values were 2-sided and considered
significant at 0.05.
Results
Study participants and samples
Twenty-seven women with confirmed uncomplicated singleton
pregnancies were included in the current study and analysis
(Table 1). These women derived from an initial population of 55
healthy women who were enrolled and followed longitudinally
throughout pregnancy, among whom complete family studies were
obtained for 35 women. After performing HLA genotyping for all
family members (n=140), families were included when the
proband did not develop any obstetric complications and the
MP had a polymorphism that was unique and testable with our
quantitative PCR panel.
The majority of women contributed two (n=6), three (n=12),
four (n=5), five (n=2), or seven (n=1) blood samples per
pregnancy, with one participant contributing one blood sample.
Pre-pregnancy blood draws were obtained up to eight months
prior to pregnancy and postpartum blood draws up to one year
after delivery.
For the preeclampsia group, 20 proband/MP pairs were
included in the study and analyzed in comparison with 20
proband/MP matched pairs with normal pregnancy. Clinical and
demographic information for the study population is provided in
Table 1. Overall, the preeclampsia population reflected that of a
tertiary care referral population, including 19/20 (95%) with
severe disease.
No participant had a prior history of blood transfusion, and
none was the recipient of an organ or hematopoietic cell
transplant, including both the healthy participants and those with
preeclampsia.
Longitudinal MP Microchimerism in Normal Pregnancy
We tested MP microchimerism in 86 PBMC samples from 27
women who were healthy and had uncomplicated pregnancies.
MP microchimerism was identified in some women at some time
points. The frequency of samples positive for MP microchimerism
during each time interval was 0% (0/6) pre-pregnancy, 0% (0/9)
in the first trimester, 16% (3/19) in the second trimester, 29% (7/
24) in the third trimester, and 14% (4/28) postpartum. The
concentration of MP microchimerism paralleled the overall
frequency of detection (Figure 2). The ranges of MP microchimer-
ism concentrations, expressed as MP microchimerism gEq per
100,000 proband gEq, for each time period: preconception, first
trimester, second trimester, third trimester, and postpartum,
respectively, were 0 - 0, 0 - 0, 0 – 6.7, 0 – 65.0, and 0 – 2.7.
While many values were zero as expected, mean concentrations of
MP microchimerism are also described as another window for
quantitative trends in MP microchimerism concentration across
gestation (though not statistically evaluated). The mean MP
microchimerism concentrations (in MP microchimerism gEq per
100,000 proband gEq) were 0 pre-pregnancy, 0 in the first
trimester, 5.1 in the second trimester, 41.8 in the third trimester,
and 1.9 postpartum. The mean total proband gEq tested among
the longitudinal normal pregnancy samples was 100,680 (standard
deviation 26,028).
For each advancing time interval, including pre-pregnancy and
each trimester of pregnancy, there was a 12.7-fold increase in the
probability of detecting MP microchimerism relative to the prior
interval [95% CI (3.2, 50.3); p,0.001]. For each additional week
of gestational age (including pre-pregnancy as week 0), the
probability increased 1.3-fold [95% CI (1.1, 1.5); p,0.001].
Visual representation of the expected concentration of MP
microchimerism in a stochastic sample of 100,000 proband cells
across gestation is shown as a spline in Figure 3.
MP Microchimerism in Preeclampsia and Matched
Controls
Of the 20 probands with preeclampsia tested for MP
microchimerism, none was positive (0/20, 0%). In comparison,
in the matched group of women with healthy pregnancies, 6/20
(30%) were positive, p=0.03. Quantitatively, the concentrations of
Pregnancy and MP Microchimerism
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Figure 4. The median MP microchimerism concentration for
both groups was 0 GEq/100,000 host cells, as expected due to the
skewed distribution. The MP microchimerism range for the
matched normal pregnancy group was 0–65.0 gEq per 100,000
proband cell equivalents, with a mean concentration of 4.8 gEq
per 100,000 proband cell equivalents. The mean totals of proband
gEq tested among the preeclampsia samples and the matched
control samples were 103,394 (standard deviation 30,373) and
100,124 (standard deviation 27,694), respectively.
Table 1. Clinical and demographic characteristics for study participants.
Longitudinal Normal
Pregnancy (n=27)
Matched Normal
Pregnancy (n=20)* Preeclampsia (n=20)
Maternal age in years, mean 6 SD 32?663?73 2 ?864?62 6 ?263?4
Nulliparity, n (%) 19 (70) 17 (85) 17 (85)
Gestational age at delivery in weeks, mean 6 SD 40?361?34 0 ?261?43 2 ?763?8
Gestational age at sample collection in weeks, mean 6 SD n/a 33?263?93 2 ?263?8
Birthweight in grams, mean 6 SD 36036470 35176538 17616921
Small for gestational age (birthweight ,10
th percentile), n (%) 2 (7) 2 (10) 13 (65)
Ethnicity, n (%)
White 25 (93) 19 (95) 17 (85)
Other 2 (7) 1 (5) 3 (15)
Cesarean delivery, n (%) 5 (19) 4 (20) 12 (60)
Prior miscarriage, n (%) 3 (11) 2 (10) 7 (35)
Prior pregnancy termination, n (%) 3 (11) 1 (5) 3 (15)
Amniocentesis, n (%) 9 (35) 5 (25) 0 (0)
Chorionic villus sampling, n (%) 1 (4) 0 (0) 0 (0)
Male fetal sex, n (%) 14 (52) 10 (50) 9 (45)
Systolic BP in mm Hg, mean 6 SD n/a n/a 162625
Diastolic BP in mm Hg, mean 6 SD n/a n/a 98613
Renal dysfunction (Cr $1?0 mg/dL or oliguria), n (%) n/a n/a 5 (25%)
Hepatic dysfunction (AST $40 U/L), n (%) n/a n/a 4 (20%)
Thrombocytopenia (platelet count ,100,000 cells/mm
3), n (%) n/a n/a 1 (5%)
Overall severe preeclampsia n/a n/a 19 (95%)
*Comparisons between preeclampsia and normal pregnancy were made with a subgroup of normal pregnancy subjects matched for parity and gestational age.
doi:10.1371/journal.pone.0024101.t001
Figure 2. Concentration of MP microchimerism gEq in a stochastic sample of 100,000 proband gEq, among subjects with normal
pregnancy, according to gestational age. Longitudinal datapoints for each subject (n=27) indicated by colored lines.
doi:10.1371/journal.pone.0024101.g002
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It has only recently been appreciated that low levels of maternal
cells, acquired during fetal life, persist into adult life in healthy
immune competent individuals [2]. Although these cells could be a
simple remnant of pregnancy without immunologic consequence,
it is of interest to consider whether cells that a woman harbors
from her own mother have the potential to influence a woman’s
pregnancies. To our knowledge, MP microchimerism has not
previously been studied in reproductive health or during the
course of normal or abnormal pregnancy. We investigated MP
microchimerism in the peripheral blood of healthy pregnant
women and found that, while MP microchimerism was not
detectable early in gestation, it was not uncommon as gestation
progressed, especially in the third trimester. We further conducted
studies of women with preeclampsia, and in contrast to healthy
pregnant women, no woman with preeclampsia had MP
microchimerism in the third trimester. These results suggest that
MP microchimerism could potentially influence pregnancy and/or
be a marker reflecting healthy maternal immune adaptation
during normal pregnancy.
Though a role for MP microchimerism in reproduction has not
previously been explored, MP microchimerism has been shown to
durably persist and to occupy diverse tissues and cell subsets with
pluripotent capacity [12,13,14,15]. In addition, pregnancy has
been shown to alter the microchimerism harbored by a woman,
with MP microchimerism declining in prevalence and concentra-
tion with increasing parity [16]. Classic experiments by Medawar
in the 1950s showed that exposure to alloantigen in fetal life
resulted in durable tolerance specific to that alloantigen [17]. That
fetal exposure to MP microchimerism can result in clinically
significant and durable tolerance in later reproductive life was
suggested in studies that were reported in the 1950s. Owen and
colleagues showed that the Rh status of a woman’s mother was
associated with her likelihood of developing alloimmunization
during pregnancy. Specifically, if a woman’s mother was Rh
positive, the chance of developing erythroblastosis was significantly
lower than if her mother was Rh negative [18]. This clinical
observation supports the hypothesis that a woman’s own in utero
exposure to Rh positive cells conferred tolerance that prevented
sensitization to Rh positive fetal cells during pregnancy.
In addition to reproductive outcomes, key evidence pointing to
long-lasting effects of maternal cells acquired during fetal life
comes from the transplantation literature. Clinical evidence
suggests better outcomes with haploidentical solid organ [19]
and hematopoietic stem-cell [20] transplants if matched to the
Figure 3. Curves indicate spline function showing model of
expected concentration of MP microchimerism gEq in a
stochastic sample of 100,000 proband gEq, according to
gestational age. Solid line indicates the point estimate of expected
microchimerism concentration, and dashed lines indicate the 95%
confidence interval. Scatterplot shows MP microchimerism concentra-
tion in proband PBMC by trimester (in gEq per 100,000 proband gEq).
doi:10.1371/journal.pone.0024101.g003
Figure 4. Concentration of MP microchimerism gEq in a stochastic sample of 100,000 proband gEq, among subjects with
preeclampsia compared with subgroup of subjects with normal pregnancy matched for gestational age (range 24–40 weeks) and
nulliparity (n=40 total), according to gestational age.
doi:10.1371/journal.pone.0024101.g004
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donors matched to the non-inherited paternal HLA antigen
(NIPA). This has been termed the NIMA effect. Recent studies
have begun to delineate the functional role of MP microchimerism
in its roles in the development of immunologic tolerance and in
conferring the NIMA effect. Data show that maternal cells
acquired by the fetus during pregnancy localize to fetal lymph
nodes, where they cause proliferation of NIMA-specific fetal T
regs [21]. The number and status of these NIMA-specific T regs
correlates with MP microchimerism [22] and predicts transplant
outcomes when NIMA-expressing allografts are subsequently
transplanted [23]. The NIMA effect can also be conferred by
infusion of NIMA-specific T regs into a non-tolerant animal [24].
The relationship between specific populations of T regs and
tolerance of allogeneic cells is also supported by a recent study that
showed colocalization of allogeneic HSC with T regs in bone
marrow, associated with engraftment, with graft rejection resulting
from selective elimination of T regs in the same model [25].
We have demonstrated an association of MP microchimerism
with reproductive outcomes. Though conceptualizing a mecha-
nistic framework for these associations is speculative, it is likely that
MP microchimerism may become detectable in peripheral blood
in normal pregnancies due to generalized stem cell mobilization,
which increases with increasing gestational age. In normal
pregnancy, potential triggers for such mobilization may be the
load of fetal antigenic material seen in the third trimester [26], the
increasing maternal blood volume and parallel need to increase
circulating red blood cell mass [27], or the mobilization of
endothelial progenitor cells seen later in gestation and that is likely
important in maintenance of endothelial health [28]. Several
possible explanations can be envisioned to underlie the relative
deficit of MP microchimerism seen in women with preeclampsia.
First, women with preeclampsia may have lower levels of MP
microchimerism within stem cell populations due to an early
deficit in acquisition of these cells during immune system
development. Second, both women with normal pregnancies
and those with preeclampsia may harbor MP microchimerism at
similar concentrations, but women with preeclampsia may have a
relative deficit in their ability to mobilize stem cells compared with
women with normal pregnancies. A third possibility is that women
with normal pregnancies and preeclampsia may both harbor and
mobilize MP microchimerism equally well, but the women with
preeclampsia may clear circulating cells more rapidly.
To our knowledge, this study provides the first description of
MP microchimerism in pregnancy, characterized in a carefully
defined longitudinal cohort of women with uncomplicated
pregnancies and compared with a well-characterized group of
women with preeclampsia. Our study limitations include feasibility
issues limiting the number of participants investigated and the
number of cells tested for each participant. We did not detect MP
microchimerism in any of the women with preeclampsia.
Statistically, we can say with 95% confidence that the probability
of a random woman with preeclampsia having detectable
microchimerism is less than 14%. This should not be interpreted
to mean that our data rule out the possibility of detection of MP
microchimerism in preeclampsia with a larger sample size, but
rather that we found a statistically significant decrease in the
overall detection and concentration in preeclampsia compared
with normal pregnancy. We found that approximately one third of
healthy women tested positively for MP microchimerism during
pregnancy. It is likely that this is an underestimation of the true
prevalence of microchimerism. Microchimerism, by definition,
occurs at very low concentrations and may occur in any tissue. For
practical reasons, we are able to test an aliquot of maternal
peripheral blood mononuclear cells (,100,000 cells), which means
that we are not detecting microchimerism sequestered in bone
marrow or other tissues. In addition, this stochastic sampling of a
rare occurrence implies that microchimerism prevalence would be
greater if larger amounts of maternal cells could be tested. In
addition, some individuals may harbor microchimerism at
concentrations below the lower limit (threshold) of detection of
the assay, again leading to generalized underestimation. There is
no reason to expect that this underestimation would vary by
gestational age or across the groups of normal pregnancy and
preeclampsia, thus rendering comparisons appropriate.
One additional point to consider is the lack of detectable MP
microchimerism in women tested prior to pregnancy in this study.
There were six subjects for whom preconception samples were
available, and none of these six had detectable MP microchimer-
ism. Given the limited number of subjects tested at this time point
in the current study, it is unlikely that there is a statistically
significant difference in this result compared with our lab’s
previous finding of 22% positivity in PBMC in healthy,
nonpregnant women [10]. In contrast, we recently demonstrated
40% detection of microchimerism within granulocytes, also in
healthy nonpregnant women [15]. Differences like this highlight
the importance of consideration of specific cell population tested
and underscore the possibility that pluripotent MP microchimer-
ism is likely to be sequestered within the bone marrow or other
tissues, rather than in peripheral circulation.
It is likely that the role of MP microchimerism in reproductive
health is complex and depends on multiple factors. For MP
microchimerism during pregnancy, multiple levels of interaction
can be envisioned. The MP microchimerism can interact with the
proband’s cells and tissues, as well as with fetal microchimerism
that is newly acquired during the pregnancy (which can also
directly interact with the proband’s cells and tissues). Our study
suggests that interactions between a pregnant woman and her
acquired microchimerism cell populations may have the potential
to influence normal reproduction and that, when awry, these
interactions may contribute to, or be a marker for, immune
dysfunction in preeclampsia.
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